Trelagliptin (SYR-472, Zafatek), Novel Once-Weekly Treatment for Type 2 Diabetes, Inhibits Dipeptidyl Peptidase-4 (DPP-4) via a Non-Covalent Mechanism
Table 3
Inhibitory activity of trelagliptin against DPP-4-related proteases.
Click through the PLOS taxonomy to find articles in your field.
For more information about PLOS Subject Areas, click here.
Inhibitory activity of trelagliptin against DPP-4-related proteases.